Drug Trial Radar · NCT02954354
A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Last checked: Nov 20, 2026Latest source record: May 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,436
Actual
Start
Dec 8, 2016
Primary completion
Apr 4, 2017
Study completion Apr 24, 2017
Sponsor
- Lead sponsor
- ShionogiIndustry
- Sponsor type
- Industry
- First posted
- Nov 3, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to alleviation of symptoms in patients with uncomplicated influenza virus infection.
Conditions
- Influenza
Interventions
Baloxavir MarboxilDrug
2 to4 X 20-mg tablets taken orally
Placebo to Baloxavir MarboxilDrug
2 to4 X 20-mg tablets taken orally
OseltamivirDrug
75 mg capsules taken orally
Placebo to OseltamivirDrug
Placebo capsules matching oseltamivir 75 mg capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Alleviation of Symptoms in Participants Randomized to Baloxavir or PlaceboTime frame: Initiation of study treatment up to Day 14
- Time to Alleviation of Symptoms in Adults Randomized to Baloxavir or OseltamivirTime frame: Initiation of study treatment up to Day 14
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.